WiSeR Model for Skin Substitutes: Medicare Prior Authorization 2026

WiSeR Model for Skin Substitutes: 2026 Update

WiSeR — Wound Care Innovative, Safe, and Effective Treatments — is a CMS mandatory prior authorization demonstration model requiring Medicare approval before applying skin substitute products (cellular and tissue-based products, CTPs) in selected states. Claims submitted without an approved prior authorization number: non-appealable denial. The claim cannot be corrected after the fact.

Financial exposure per unauthorized application: $500–$5,000+ depending on the product.

What WiSeR PA Requires

Submit all of the following before the date of service:

Wound type documentation — most covered products require DFU (diabetic foot ulcer) or VLU (venous leg ulcer)
30+ days of documented standard wound care with documented inadequate healing response
Serial measurements showing less than 50% area reduction at 4 weeks of conservative treatment
ABI (ankle-brachial index) for all lower extremity wound patients — vascular status required
Specific product name and Q code you intend to apply
Offloading compliance documentation for DFUs; vascular treatment plan for VLUs

Processing timeline: Standard 3–10 business days. Expedited review: 24–72 hours (requires documented clinical urgency). Submit at least 5 business days before planned application date.

The Rules That Cannot Be Bent

PA must be approved before the date of service. No retroactive authorization. The visit happens, the authorization is denied or pending, and the claim cannot be billed. The product cost is a complete loss.

PA is product-specific. If you switch from Product A to Product B — even for a clinically justified reason — you need a new PA for Product B approved before application. The PA for Product A does not transfer.

30-day documentation must precede the application. Serial measurements with dates and tissue composition percentages on each measurement date. A note that says "standard wound care provided for 30 days" without dated measurement records will not satisfy PA reviewers.

Most Common PA Denial Reasons

Inadequate conservative wound care documentation (60%+ of denials): Notes exist but lack serial measurements with dates, wound dimensions, and tissue progression. The PA reviewer needs to see wound size at week 0, week 2, week 4, with calculation showing less than 50% reduction.

Missing ABI (25% of denials): Required for all lower extremity wounds. An ABI reference from 6 months prior is generally accepted; check your MAC's specific requirement.

Wound type mismatch (10% of denials): Product Q code submitted for a wound type not covered under that product's LCD indication.

Formulary Management in WiSeR States

For each patient who may need a skin substitute, obtain PA for your primary product AND one backup before scheduling the application visit. If the primary product is unavailable on the day of service, you have an approved alternative. You cannot substitute without approved PA.

Maintain a narrow, well-authorized formulary — 3–4 products you know your MAC approves efficiently. Broad formularies create authorization management complexity that delays care.